Clinical Trial Update: Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes [Phase 1]

View source ↗

Summary

Phase 1 study of ENT-03, a subcutaneously administered therapy from Metabolics Pharma, for obesity and Type 2 Diabetes Mellitus is currently active but not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• ENT-03

Snippet

Sponsor: Metabolics Pharma | Conditions: Obesity, Diabetes Mellitus, Type 2 | Phase 1 | Status: ACTIVE_NOT_RECRUITING